目的观察氟哌噻吨美利曲辛片联合埃索美拉唑、莫沙必利在女性慢性胃炎患者中的治疗效果，并对患者的焦虑和抑郁状态改善程度进行评分。方法选择2011年1月至2014年10月两院门诊及入院治疗的符合入组标准的118例女性慢性胃炎患者为研究对象，随机分为试验组（50例）和对照组（68例）。试验组患者给予氟哌噻吨美利曲辛片、埃索美拉唑镁肠溶片、枸橼酸莫沙必利分散片口服，对照组患者给予埃索美拉唑镁肠溶片和枸橼酸莫沙必利片口服。疗程均为4周。分别对患者治疗前后的胃肠道症状及焦虑、抑郁状态进行胃肠功能症状分级量表-C类（GSRS-C）、汉密尔顿焦虑量表（HAMA）和汉密尔顿抑郁量表（HAMD）量化评分。结果治疗后，两组患者胃肠道症状及焦虑、抑郁状态均较治疗前显著改善（P＜0.05），且试验组较对照组改善效果更明显（P＜0.05）。结论氟哌噻吨美利曲辛片联合埃索美拉唑、莫沙必利治疗女性慢性胃炎伴焦虑及抑郁症状，能够取得显著效果，患者胃肠道症状和焦虑、抑郁状态改善较明显，耐受性好。%Objective To discuss the clinical curative effect of lfupentixol and melitracen tablets combined with esomeprazole magnesium and mosapride on the treatment of women with chronic gastritis, and to discuss the intervention efifcacy on anxious and depressed mood of these patients. Method 118 cases famle patients with chronic gastritis outpatients and inpatients in our hospital were divided randomly into experimental group and control group from January 2011 to October 2014. The patients in experimental group members were given lfupentixol and melitracen tablets, esomeprazole and mosapride. The patients in control group were given esomeprazole and mosapride. The treatment lasted for 4 weeks. Pretherapy and post-treatment, patients were given the GSRS-C, HAMA and HAMD evaluation. Result The scores of the two groups were signiifcantly decreased than the beginning and experimental group's scores were significantly lower than control group (P < 0.05). Conclusion Flupentixol and melitracen tablets combined with esorneprazole magnesium and mosapride has a more significant clinical curative effect on the treatment of chronic gastritis patients with gastrointestinal symptoms, anxiety and depression can improved signiifcantly, well tolerated.
展开▼
